OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
14
Results
Show all
Save search
Copy query
Show results for
Unknown
(14)
Publication Date
Release Date
2025
(3)
2023
(3)
2015
(3)
2021
(2)
2016
(1)
2014
(1)
2011
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Not available
S-EPMC10837320
|
biostudies-literature
Cite
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.
Not available
S-EPMC5340115
|
biostudies-literature
Cite
The Psychological Science Accelerator's COVID-19 rapid-response dataset.
Not available
S-EPMC9918828
|
biostudies-literature
Cite
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
Not available
S-EPMC4105321
|
biostudies-literature
Cite
A multi-country test of brief reappraisal interventions on emotions during the COVID-19 pandemic.
Not available
S-EPMC8742248
|
biostudies-literature
Cite
Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC).
Not available
S-EPMC4722961
|
biostudies-literature
Cite
Assessment of Baseline Ultrawidefield Fluorescein Angiographic Quantitative Leakage Parameters with Ultrawidefield Fundus Features and Clinical Parameters in Diabetic Retinopathy in Protocol AA.
Not available
S-EPMC11868455
|
biostudies-literature
Cite
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.
Not available
S-EPMC4478717
|
biostudies-literature
Cite
Identification of six new susceptibility loci for invasive epithelial ovarian cancer.
Not available
S-EPMC4445140
|
biostudies-literature
Cite
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets